Role of Immunohistochemistry (IHC) in Round Blue Cell Tumors (RBCTs)

What Are Round Blue Cell Tumors?

Round blue cell tumors are a group of high-grade malignancies that share identical morphology on H&E staining: sheets of small, uniform, hyperchromatic cells with scant cytoplasm and inconspicuous nucleoli. Because morphology alone cannot distinguish them, IHC is indispensable for accurate diagnosis, which directly drives treatment.

The main tumors in this category include:

Ewing sarcoma / PNET
Neuroblastoma
Rhabdomyosarcoma (RMS)
Non-Hodgkin lymphoma / leukemia
Wilms tumor (nephroblastoma)
Desmoplastic small round cell tumor (DSRCT)
Medulloblastoma
Small cell carcinoma (in adults)
Merkel cell carcinoma

Why IHC Is Essential

IHC relies on an antibody-antigen reaction visualized by enzyme-chromogen complexes. As emphasized in Fishman's Pulmonary Diseases: "It is diagnostically irrelevant to speak of overall sensitivity and specificity for a particular antibody. Rather it is appropriate to speak of relative sensitivity and specificity within a particular differential diagnosis." A targeted panel - not a single marker - is always used, interpreted in clinical and morphologic context.

IHC Markers by Tumor

1. Ewing Sarcoma / PNET

Marker	Result	Notes
CD99 (MIC2)	Strong diffuse membranous +	Most sensitive marker; ~95% positive; not specific alone
FLI1	Nuclear +	Reflects EWS-FLI1 fusion gene product
NKX2.2	Nuclear +	Highly useful in sinonasal and small round cell lesions; helps distinguish from other RBCTs
Synaptophysin	Focal +	Reflects neuroectodermal lineage in PNET
Keratin, desmin	Negative	Helps exclude RMS, carcinoma

The characteristic translocation t(11;22)(q24;q12) producing the EWS-FLI1 fusion is the molecular gold standard, and FLI1/CD99 IHC is the surrogate marker panel. - Miller's Review of Orthopaedics, p. 826

2. Rhabdomyosarcoma (RMS)

Marker	Result	Notes
Desmin	+	Muscle lineage marker
Myogenin (Myf-4)	Nuclear +	Highly specific for skeletal muscle differentiation
MyoD1	Nuclear +	Myogenic regulatory protein; very specific
Vimentin	+	Non-specific but usually positive
CD99	Can be +	Must not be used alone

Myogenin and MyoD1 are the most specific markers. In alveolar RMS (ARMS), ~70% harbor t(2;13)(q35;q14) fusing PAX3-FOXO1. Histologic subtyping (embryonal, alveolar, pleomorphic) requires IHC and molecular testing. - Henry's Clinical Diagnosis, p. 1367; Miller's, p. 826

3. Neuroblastoma

Marker	Result	Notes
Synaptophysin	+	Neuroendocrine differentiation
Chromogranin A	+	Neuroendocrine
NSE (Neuron-specific enolase)	+	Sensitive but not specific
NB84	+	Relatively specific for neuroblastoma
S100	+ in sustentacular cells
CD99, desmin, myogenin	Negative	Key exclusion

IHC findings combined with tumor-specific genetic translocations (e.g., MYCN amplification) help definitively confirm or exclude neuroblastoma. - Tietz Textbook of Laboratory Medicine

4. Lymphoma / Leukemia (ALL)

Marker	Result	Notes
CD45 (LCA)	+	Leukocyte common antigen; most important exclusion marker
CD20	+	B-cell lymphoma
CD3, CD5	+	T-cell lymphoma
TdT	+	Precursor B or T lymphoblastic lymphoma
CD10	+	B-ALL, follicular lymphoma
Keratin, desmin	Negative

CD45 is the first marker to check in any RBCT panel - positivity essentially confirms lymphoid origin.

5. Desmoplastic Small Round Cell Tumor (DSRCT)

Marker	Result	Notes
Keratin (AE1/AE3)	+	Epithelial component
Desmin	+ in dot-like paranuclear pattern	Characteristic!
Vimentin	+
WT1 (C-terminus)	+	Reflects EWS-WT1 translocation
NSE, synaptophysin	Focal +
MyoD1, myogenin	Negative	Distinguishes from RMS

The co-expression of epithelial (keratin), mesenchymal (desmin, vimentin), and neural markers is unique to DSRCT. The t(11;22)(p13;q12) produces EWS-WT1 fusion.

6. Wilms Tumor (Nephroblastoma)

Marker	Result	Notes
WT1	+ (N-terminus)
Keratin, EMA	+	Epithelial elements
Vimentin	+	Stromal elements
CD99	Variable

7. Small Cell Carcinoma (in adults)

Marker	Result	Notes
Pancytokeratin (AE1/AE3, CAM5.2)	+	Epithelial origin
Synaptophysin, chromogranin	+	Neuroendocrine
TTF-1	+ (lung primary)	Site of origin
CD45	Negative	Excludes lymphoma

8. Merkel Cell Carcinoma

Marker	Result	Notes
CK20	Dot-like paranuclear +	Highly characteristic
CD56	+
Synaptophysin, chromogranin	+
CK7	Negative	Distinguishes from small cell lung carcinoma

Practical Approach: A Stepwise IHC Panel

A rational tiered approach to any RBCT:

Tier 1 - Lineage assignment (run first):

CD45 (LCA) - lymphoid?
Pancytokeratin - epithelial/DSRCT?
CD99 - Ewing/PNET?
Synaptophysin - neuroendocrine/neural?
Desmin - muscle?

Tier 2 - Subclassification (based on Tier 1 results):

If CD99+: add FLI1, NKX2.2, keratin (to exclude synovial sarcoma)
If desmin+: add myogenin, MyoD1 (to confirm RMS)
If synaptophysin+: add chromogranin, NSE, NB84 (neuroblastoma vs carcinoid)
If keratin+: add WT1, CK20, TTF-1 (DSRCT vs Merkel vs small cell carcinoma)
If CD45+: add TdT, CD20, CD3, CD10 (lymphoma subtyping)

Tier 3 - Molecular confirmation:

FISH/RT-PCR for translocations: EWS-FLI1 (Ewing), PAX3/7-FOXO1 (ARMS), EWS-WT1 (DSRCT)
NGS-based fusion gene panels in ambiguous cases

Summary Table

Tumor	Key Positive Markers	Key Negative Markers
Ewing sarcoma	CD99, FLI1, NKX2.2	Desmin, myogenin, CK (usually)
Neuroblastoma	Synaptophysin, chromogranin, NSE, NB84	CD45, desmin, myogenin
Rhabdomyosarcoma	Desmin, myogenin, MyoD1	CD45, CD99 (usually)
Lymphoma (ALL/LBL)	CD45, TdT, CD20/CD3	Desmin, keratin, myogenin
DSRCT	Keratin, desmin (dot), WT1, vimentin	MyoD1/myogenin
Wilms tumor	WT1, keratin, vimentin	CD45, myogenin
Small cell carcinoma	Keratin, synaptophysin, TTF-1	CD45, desmin
Merkel cell carcinoma	CK20 (dot), CD56, synaptophysin	CD45, CK7

Key Points

No single marker is pathognomonic - always use a panel and interpret in context.
CD99 is highly sensitive for Ewing sarcoma but is also expressed in lymphoblastic lymphoma, RMS, and synovial sarcoma - cannot be used alone.
Myogenin and MyoD1 are the most specific markers for RMS because they are nuclear transcription factors unique to skeletal muscle lineage.
DSRCT has a unique co-expression pattern mimicking multiple lineages simultaneously (keratin + desmin + vimentin + WT1).
Molecular testing (FISH, RT-PCR, NGS) is now used alongside IHC as a complementary/confirmatory tool, especially when IHC results are equivocal.

Sources: Miller's Review of Orthopaedics 9th Ed., p. 826; Fishman's Pulmonary Diseases; Henry's Clinical Diagnosis and Management; Tietz Textbook of Laboratory Medicine; Robbins Pathologic Basis of Disease

This is a shared conversation. Sign in to Orris to start your own chat.